about
Role of stem cells during diabetic liver injuryMolecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisalTherapeutic targets of brain insulin resistance in sporadic Alzheimer's diseasePer-Arnt-Sim Kinase (PASK): An Emerging Regulator of Mammalian Glucose and Lipid MetabolismBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's diseaseEpidemilogical trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis.Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's diseaseNitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration.An ErChen and YinChen Decoction Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis in Rats by Regulating JNK1 Signaling Pathway.Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitisAlzheimer's disease is type 3 diabetes-evidence reviewed.Genetic determinants of hepatic steatosis in man.The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndromePostprandial Responses to Lipid and Carbohydrate Ingestion in Repeated Subcutaneous Adipose Tissue Biopsies in Healthy Adults.Brain metabolic dysfunction at the core of Alzheimer's disease.Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center.Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease.Health benefits of blue-green algae: prevention of cardiovascular disease and nonalcoholic fatty liver disease.Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats.Low educational status, smoking, and multidisciplinary team experience predict hospital length of stay after bariatric surgeryNonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations PatientsNon alcoholic fatty liver disease and metabolic syndrome.High glucose upregulates BACE1-mediated Aβ production through ROS-dependent HIF-1α and LXRα/ABCA1-regulated lipid raft reorganization in SK-N-MC cells.Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant miceInsulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.Hepatic steatosis and steatohepatitis: Are they really two distinct entities?Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease.Pentoxifylline for steatohepatitis: magic bullet or smoking gun?Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease.Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice.circRNA_0046366 inhibits hepatocellular steatosis by normalization of PPAR signaling.Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis.The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease.
P2860
Q26773551-DB7F5E80-0D76-4C37-866D-0933AACF3EC3Q26783344-64E0BA3F-3C25-4AA6-A69D-6554C786C021Q27021700-B129BC5B-2E8B-4540-BA35-C58692436BDCQ28085060-120F583A-BA1F-4A88-94FA-6685C64878D8Q28259585-88AC7E3B-69FE-4C76-A0BA-A089955074E4Q30376120-090407F2-6ED9-4F94-9329-92A8CB6597EBQ30479198-CA75B98C-419F-430E-935D-94254E2F0F4DQ30484122-45771E51-959E-4B0B-8B08-EB89FFD5AA5CQ33543381-087DD7F8-A682-4318-9668-3E86E31044EFQ33819857-AB1B33F9-D5F3-4368-BC18-3BF7D68DE829Q33944689-2EE2981A-1A7A-4C44-9B0D-F736FC12866AQ34020000-0C9545C9-5515-4A80-BA9F-AA50CBD1D3FDQ34646183-353D6D46-23EC-4F55-929A-06A427F5AFFFQ35090416-A58150D2-C4D4-4A4C-8326-138009DECC71Q35872059-17868D2F-FB92-4840-B40B-01133E3EC6F8Q35894983-BC4BFC24-1FB6-4A3C-B2EA-EC01753DE994Q35997881-993113D2-A77B-4E21-B478-71CC93C27C07Q36473562-C1157E2D-3DC1-4B48-B46E-2544ADA5DF72Q36502250-F6DC0943-9976-473B-A9AB-FF5CC37BC79BQ36623024-7F91033B-5E1E-4397-8447-5B2A96E765B9Q36841315-1CEC9150-9D4B-4A60-BD5C-CDAD96CD81F8Q36973504-D0DDC08C-5FD5-4E2C-9012-9A9258B150F1Q36996996-88E7A94B-6E49-4C6D-8CA1-7C0E93AC1439Q37078311-08E48B4B-A56E-4ABE-B940-A7B9AF0896C0Q37405573-EEA33D01-DEBE-4D49-B37A-54D253F33575Q37444112-6393343E-35C8-48B5-B26B-CF2DEADE359DQ37602608-28A16327-0E5E-49A5-829A-AE871370F4E8Q38000540-0E8BB7E7-BF5A-4F55-AD70-E4F2A4629EE1Q38224490-70D44E3A-0DC8-4CC7-B890-AB49B925161AQ38443746-2C3B3AE0-9424-4860-8BBA-0A447929DF85Q41697003-CE7C67EB-6890-4A31-BCA8-CAB136A5691EQ42097807-48B562C3-04C5-40CC-8495-22E90DCA059CQ42734634-F2C4E7C2-0FD5-4889-AF5C-8572D158B8A0Q43225410-0E20E1CC-B271-4F00-81C6-5C3F96A24EDDQ45789410-4B2D9E77-F14B-4640-A9F4-A0FC3FB6F54DQ47555750-0133F0D0-C1F0-406B-B54F-076E467EAB01Q47718804-A9235D78-7260-4D0F-BED8-6EE8FB254DA9Q49387786-8CA8020F-08C5-4925-AAE3-518D069C1926Q50134501-580A79DE-CC81-41BC-894E-0108B2807AEBQ51321244-FD52F3CF-A590-4EB3-8E09-C8678A977010
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Metabolic syndrome and NASH.
@en
type
label
Metabolic syndrome and NASH.
@en
prefLabel
Metabolic syndrome and NASH.
@en
P1476
Metabolic syndrome and NASH.
@en
P2093
Rebecca Marzocchi
P304
105-17, ix
P356
10.1016/J.CLD.2007.02.013
P577
2007-02-01T00:00:00Z